New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
09:22 EDTTNXPTonix Pharmaceuticals reports Q4 EPS (74c), one estimate (46c)
Seth Lederman, M.D., president and CEO of Tonix stated, "In Q4, Tonix continued to make steady progress in the BESTFIT trial of TNX-102 SL in fibromyalgia, and we began an open-label extension study of trial completers. As recruitment has proceeded ahead of our projections, we plan to stop enrollment at approximately 200 subjects, which is the upper end of the original sample size. We anticipate reporting top-line results of BESTFIT in the fourth quarter of this year. On March 26, the FDA held a public meeting on Patient-Focused Drug Development for fibromyalgia. FDA's decision to hold this meeting, and the robust patient response to it, further validate our belief that fibromyalgia is a significant and growing medical concern among the U.S. population."
News For TNXP From The Last 14 Days
Check below for free stories on TNXP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for TNXP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use